NeuBase Therapeutics (NBSE) 10-Q2010 Q1 Quarterly report

Filed: 16 Feb 10, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. sophomore Avg

New words: addressed, allocation, amino, animal, arrangement, ASC, ASU, award, bank, bond, cancer, cardiovascular, chemical, classified, composed, Contemplation, counterparty, covalently, cover, decrease, default, derivative, diadenosine, dinucleotide, disposed, Emerging, enable, equivalent, EVIZONTM, favorable, final, Genaera, Hirshman, human, immunomodulator, inducement, intraocular, lender, long, lower, McGill, mechanism, modified, ophthalmic, ownership, patent, Peptide, percent, permitted, phosphodiester, predecessor, profile, prospectively, ranging, ratified, reached, recoverability, recoverable, recovered, reincorporation, rendered, repaid, represent, retrospective, retrospectively, safety, scope, separate, separated, separately, serine, settlement, side, singular, Squalamine, stable, structure, Subtopic, sufficient, tangible, Task, therapy, toxicity, transpire, Trodusquemine, Trust, twelve, undiscounted, unique, wasting, worth

Removed: agreed, agreeing, authoritative, authority, broadband, cancellation, candidate, claim, combination, condition, contract, corporate, customer, director, discussed, employment, enterprise, Hierarchy, implied, industry, internet, interpretation, Item, largest, law, lease, level, liability, Lightspace, maritime, merged, notification, November, payable, point, primarily, pronouncement, reduced, relating, release, security, Selling, service, shell, suitable, suspend, transaction, Utah, warranty, withdraw

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

NBSE similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

Certification of Chief Financial Officer

Pursuant to 18 U.S.C Section 1350,

As Adopted Pursuant to Section 906 of the

Sarbanes-Oxley Act of 2002

Not Filed Pursuant to the Securities Exchange Act of 1934

In connection with the Quarterly Report of Ohr Pharmaceutical, Inc (the “Company”) on Form 10Q for the period ending December 31, 2009, as filed with the Securities and Exchange Commission on the date hereof )the “Report”), I, Andrew Limpert, Chief Financial Officer, and Secretary/Treasurer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1.	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Date February 16, 2010	By:	/s/ Andrew Limpert
		Name Andrew Limpert
		Title Interim Chief Financial Officer